ICON Announces The Acquisition Of Healthcare Discoveries Inc
11 Fevereiro 2008 - 4:11PM
Business Wire
ICON (NASDAQ:ICLR), a global provider of outsourced development
services to the pharmaceutical, biotechnology and medical device
industries, today announced that it has acquired Healthcare
Discoveries Inc, a wholly owned subsidiary of Catalyst Pharma Group
Inc. Under the terms of the agreement ICON will pay an initial cash
consideration of $12M. If certain performance milestones are
achieved in 2008, a further consideration, up to a maximum of $10m
may be payable. Healthcare Discoveries operate an 85 bed clinical
pharmacology unit in San Antonio, Texas and have significant
experience of delivering high quality early phase development
programmes. �The acquisition of Healthcare Discoveries is an
important step for ICON� commented ICON CEO Peter Gray. �It gives
us a clinical pharmacology platform in the United States to
complement our existing European Phase I operations. As well as
gaining an outstanding facility, we are bringing into ICON an
experienced team that has an excellent market reputation�
Healthcare Discoveries will become part of a comprehensive early
phase development portfolio within the ICON Development Solutions
division, which includes an existing 80 bed clinical pharmacology
unit based in Manchester, England. Dr Thomas Frey, President of
this division, added �The investment in Healthcare Discoveries will
enable us to meet the growing demand for highly scientific
first-in-human and full spectrum of clinical pharmacology studies
that are a critical part of the drug development process. We look
forward to integrating these additional capabilities into our broad
drug development service portfolio� Dr Richard Anthony, CEO of
Catalyst Pharma Group commented �We are delighted that Healthcare
Discoveries will become part of the ICON group. Catalyst has worked
with Dr. Dennis Ruff, President of Healthcare Discoveries, for the
past four years to build a reputation for excellence in Phase I
research�. Dr. Anthony added �We believe ICON�s early phase
development experience, focus on quality and business culture is an
ideal fit with Healthcare Discoveries. Catalyst looks forward to
continuing to work with Healthcare Discoveries in the future�.
About ICON plc ICON plc is a global provider of outsourced
development services to the pharmaceutical, biotechnology and
medical device industries. The Company specializes in the strategic
development, management and analysis of programs that support
clinical development - from compound selection to Phase I-IV
clinical studies. ICON teams have successfully conducted over 1,900
development projects and over 2,300 consultancy engagements across
all major therapeutic areas. ICON currently has approximately 5,600
employees, operating from 67 locations in 37 countries. Further
information is available at www.iconplc.com About Catalyst Pharma
Group Inc Catalyst Pharma Group Inc. (Catalyst) was formed
specifically to meet the needs of companies with limited United
States presence which are seeking to develop, approve, and market
pharmaceuticals in the U.S. CPG is a drug development services
organization specializing in providing contiguous, integrated,
cost-effective drug development solutions through internal
divisions and the combined services of our partnered companies. For
more information visit http://www.catalystpharmagroup.com
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024